Therapeutics Company Announces Licensing Agreement With Gilead Sciences
Gilead Sciences and Xilio Therapeutics Forge Path in Cancer Treatment with Tumor-Activated IL-12 Program.
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.